C9028 Injection, inotuzumab ozogamicin, 0.1 mg

Name of the Procedure:

Injection of Inotuzumab Ozogamicin, commonly referred to in medical terms as an Injection of Antibody-Drug Conjugate (C9028).

Summary

The procedure involves injecting a medication known as inotuzumab ozogamicin, which is a targeted therapy designed to treat certain types of leukemia. This medication combines a potent anti-cancer drug with an antibody that specifically targets cancer cells.

Purpose

• Medical Conditions: This injection is primarily used to treat B-cell acute lymphoblastic leukemia (ALL).
• Goals: The main goal is to target and kill cancer cells with minimal damage to surrounding healthy tissues, thereby reducing the leukemia cell count and improving the patient's prognosis.

Indications

• Symptoms/Conditions: Inotuzumab ozogamicin is indicated for patients who have relapsed or refractory B-cell acute lymphoblastic leukemia.
• Patient Criteria: Typically recommended for patients who do not respond to standard leukemia treatments or whose cancer has returned.

Preparation

• Pre-Procedure Instructions: Patients may be advised to fast for a few hours before the procedure and avoid certain medications that might interfere with the treatment.
• Diagnostic Tests: Blood tests and imaging studies are typically conducted to assess the patient’s overall health and to confirm the diagnosis and extent of leukemia.

Procedure Description

1. Initial Assessment: A nurse or doctor will review the patient’s medical history and current health status.
2. Intravenous Line (IV): An IV line is placed into a vein in the patient's arm.
3. Preparation of Medication: The inotuzumab ozogamicin solution is prepared by a pharmacist or healthcare provider.
4. Administration: The medication is slowly injected through the IV line over 1 hour.
5. Monitoring: The patient’s vital signs are monitored throughout the infusion to watch for any adverse reactions.

• Tools/Equipment: IV setup, infusion pumps, monitoring devices.
• Anesthesia/Sedation: Not typically required, but local numbing cream may be used to alleviate IV insertion discomfort.

Duration

The actual infusion takes about 1 hour, but the entire visit may last several hours due to preparation, monitoring, and post-procedure observations.

Setting

The procedure is usually performed in an outpatient clinic or a hospital’s oncology unit.

Personnel

• Healthcare Professionals: Oncologists, infusion nurses, pharmacists, and medical assistants may be involved in the procedure.

Risks and Complications

• Common Risks: Fever, nausea, fatigue, low blood cell counts.
• Rare Risks: Severe allergic reactions, liver damage, infusion-related reactions, and infections.

Benefits

• Expected Benefits: Reduction in leukemia cell count, improved response rates, and potentially prolonged survival.
• Timeframe for Benefits: Patients may start to see improvements within a few weeks to months, depending on their individual response.

Recovery

• Post-Procedure Care: Patients may need to stay for observation in the clinic/hospital for a few hours post-infusion.
• Recovery Time: Some patients might experience immediate fatigue, and it is advisable to rest for the remainder of the day.
• Restrictions/Follow-Up: Regular blood tests and follow-up appointments are necessary to monitor response and detect any side effects early.

Alternatives

• Other Treatments: Chemotherapy, stem cell transplantation, other targeted therapies, or participation in clinical trials.
• Pros and Cons: Alternatives might be less targeted and can have wider systemic effects compared to inotuzumab ozogamicin, but they may still be effective depending on the case.

Patient Experience

• During Procedure: Patients may feel a slight discomfort when the IV is inserted; some might experience mild side effects like nausea.
• After Procedure: Patients are likely to feel tired and need to rest. Pain management options and comfort measures will be provided as needed.